Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world
Americas+1 212 318 2000
EMEA+44 20 7330 7500
Asia Pacific+65 6212 1000
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world
Americas+1 212 318 2000
EMEA+44 20 7330 7500
Asia Pacific+65 6212 1000
Romaine Bostick breaks down the day's top stories and trading action leading into the close.
Insight and analysis of top stories from our award winning magazine "Bloomberg Businessweek".
Highlights from a week-long virtual event bringing Bloomberg Businessweek magazine to life. Carol Massar and Tim Stenovec host a look back at the best interviews, discussions and more.
Cargill, Dreyfus and Cofco Tell Argentina to Loosen Its Grip on Soy
Here’s Why Insurers Are Leaving Disaster-Prone Places
Argentina Economy Grew in July Despite Recession on Horizon
Cost-of-Living Stress Fuels Crime Wave in Australia, New Zealand
Fed’s Bowman Says High Rent Burden Shows Need to Cool Inflation
Film academy gifts a replacement of Hattie McDaniel's historic Oscar to Howard University
The Rise of the Electric Two-Wheeler
OpenAI Seeks $90 Billion Valuation in Possible Share Sale, WSJ Says
FTC Case Against Amazon Hinges on ‘Online Superstore’ Label
FTC Sues Amazon in Landmark Antitrust Case Over Marketplace
CIA Builds Its Own Artificial Intelligence Tool in Rivalry With China
Google DeepMind Alum Raises $14 Million for New AI Venture Firm
Getty Images to Debut Its Own Artificial Intelligence Image Generator
US Government Shutdown Poised to Delay Billions From Biden’s Climate Law
Virginia’s Glenn Youngkin Signals Interest in Offices Beyond Governor
Levi Strauss Heir Daniel Lurie Enters San Francisco Mayoral Race
What You Need to Know About the New Rules for College Admissions
Whether Schmoozing or Just Boozing, There’s a Wine Club for That
Woody Harrelson Releases Vodka, Gin Made From Artichoke Leaves
The FTC Makes Merger Arb More Fun
Lina Khan Isn’t Wrong About Amazon
Automakers, It Won’t Hurt to Share That Buyback Bounty
Who’s Afraid of $100 Oil?
Why Retiring in India No Longer Requires Living With the Kids
A Key American Plant Making Antibiotics for Kids Risks Shutting Down
Viola Davis, Ex-Walgreens CEO Join Council on African Diaspora
JPMorgan Settles With Jes Staley, US Virgin Islands to End Epstein Legal Woes
What Is El Niño and How Does it Affect Weather Around the World?
World’s No. 1 Stock Owner Calls Out Big Oil as Carbon Levels Go Up
Florida Overtakes New York as Second-Biggest US Housing Market
California and New York Risk Budget Cuts When Pandemic Aid Ends, Report Says
The Local Leaders Bringing Generative AI to City Hall
Stablecoin Issuers Risk Disrupting Funding Markets, JPMorgan Says
JPMorgan to Block Crypto Payments From Chase UK Bank Accounts
Binance Seeks to Launch Stablecoins in Japan with MUFG Unit
Lagevrio, also known as molnupiravir, works by creating mutations in the Covid genome to prevent the virus from replicating, reducing its ability to cause severe illness.
Merck & Co.’s antiviral Lagevrio is linked to specific genetic changes in the virus that causes Covid-19, researchers said, raising questions about whether the drug has the potential to accelerate how quickly the coronavirus mutates.
Viral samples from patients who took the drug show a “signature mutation profile,” meaning changes were triggered by the drug, the authors said Monday in the journal Nature. The findings adds weight to earlier work by the same team of researchers that suggested that drug-induced mutations of Covid were spreading in some populations, although not in great numbers.